Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Goldin

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
Radiology|May 16, 2019
Components of Radiologic Progressive Disease Defined by RECIST 1.1 in Patients with Metastatic Clear Cell Renal Cell CarcinomaHeidi J Coy, Michael L Douek, Kathleen Ruchalski, et al.
Physics in Medicine and Biology|March 7, 2024
Motion compensated cone-beam CT reconstruction using an<i>a priori</i>motion model from CT simulation: a pilot studyMichael Lauria, Claudia Miller, Kamal Singhrao, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|July 14, 2022
Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progressionKathleen Ruchalski, Hyun J Kim, Michael Douek, et al.
The European Respiratory Journal|March 12, 2016
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosisGanesh Raghu, Mary Beth Scholand, João de Andrade, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2007
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCharlie Strange, Marcy B Bolster, Michael D Roth, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Chest|December 26, 2016
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study IIDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Respiratory Research|February 11, 2022
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trialDave Singh, Jim M Wild, Dinesh Saralaya, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Radiology|May 16, 2019
Components of Radiologic Progressive Disease Defined by RECIST 1.1 in Patients with Metastatic Clear Cell Renal Cell CarcinomaHeidi J Coy, Michael L Douek, Kathleen Ruchalski, et al.
Physics in Medicine and Biology|March 7, 2024
Motion compensated cone-beam CT reconstruction using an<i>a priori</i>motion model from CT simulation: a pilot studyMichael Lauria, Claudia Miller, Kamal Singhrao, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|July 14, 2022
Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progressionKathleen Ruchalski, Hyun J Kim, Michael Douek, et al.
The European Respiratory Journal|March 12, 2016
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosisGanesh Raghu, Mary Beth Scholand, João de Andrade, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2007
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCharlie Strange, Marcy B Bolster, Michael D Roth, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Chest|December 26, 2016
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study IIDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Respiratory Research|February 11, 2022
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trialDave Singh, Jim M Wild, Dinesh Saralaya, et al.
Pageof 11